Carcinoma, Non-Small-Cell Lung
"Carcinoma, Non-Small-Cell Lung" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
| Descriptor ID |
D002289
|
| MeSH Number(s) |
C04.588.894.797.520.109.220.249 C08.381.540.140.500 C08.785.520.100.220.500
|
| Concept/Terms |
Carcinoma, Non-Small-Cell Lung- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Non Small Cell Lung
- Carcinomas, Non-Small-Cell Lung
- Lung Carcinoma, Non-Small-Cell
- Lung Carcinomas, Non-Small-Cell
- Non-Small-Cell Lung Carcinomas
- Nonsmall Cell Lung Cancer
- Non-Small-Cell Lung Carcinoma
- Non Small Cell Lung Carcinoma
- Carcinoma, Non-Small Cell Lung
- Non-Small Cell Lung Cancer
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Non-Small-Cell Lung".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Non-Small-Cell Lung".
This graph shows the total number of publications written about "Carcinoma, Non-Small-Cell Lung" by people in this website by year, and whether "Carcinoma, Non-Small-Cell Lung" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 15 | 1 | 16 |
| 1996 | 11 | 4 | 15 |
| 1997 | 13 | 6 | 19 |
| 1998 | 14 | 3 | 17 |
| 1999 | 18 | 6 | 24 |
| 2000 | 24 | 5 | 29 |
| 2001 | 27 | 7 | 34 |
| 2002 | 32 | 5 | 37 |
| 2003 | 41 | 6 | 47 |
| 2004 | 53 | 5 | 58 |
| 2005 | 51 | 8 | 59 |
| 2006 | 54 | 11 | 65 |
| 2007 | 60 | 8 | 68 |
| 2008 | 72 | 8 | 80 |
| 2009 | 69 | 5 | 74 |
| 2010 | 69 | 11 | 80 |
| 2011 | 86 | 7 | 93 |
| 2012 | 83 | 12 | 95 |
| 2013 | 94 | 8 | 102 |
| 2014 | 87 | 5 | 92 |
| 2015 | 85 | 10 | 95 |
| 2016 | 73 | 7 | 80 |
| 2017 | 75 | 8 | 83 |
| 2018 | 90 | 11 | 101 |
| 2019 | 87 | 7 | 94 |
| 2020 | 114 | 8 | 122 |
| 2021 | 105 | 5 | 110 |
| 2022 | 107 | 2 | 109 |
| 2023 | 120 | 2 | 122 |
| 2024 | 66 | 11 | 77 |
| 2025 | 3 | 1 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carcinoma, Non-Small-Cell Lung" by people in Profiles.
-
Occult metastases and survival of lung cancer by clinical diagnosis and CT screening: A simulation study. PLoS One. 2025; 20(1):e0313544.
-
Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial. Nat Commun. 2025 Jan 02; 16(1):93.
-
A rapid turnaround time workflow for a cytological liquid biopsy assay using FNA supernatant specimens. Cancer Cytopathol. 2025 Jan; 133(1):e22925.
-
Pan-cancer genomic analysis reveals FOXA1 amplification is associated with adverse outcomes in non-small cell lung, prostate, and breast cancers. J Natl Cancer Inst. 2025 Jan 01; 117(1):188-197.
-
High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC. J Immunother Cancer. 2024 Dec 25; 12(12).
-
Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial. Signal Transduct Target Ther. 2024 Dec 24; 9(1):369.
-
Real-World and Clinical Trial Validation of a Deep Learning Radiomic Biomarker for PD-(L)1 Immune Checkpoint Inhibitor Response in Advanced Non-Small Cell Lung Cancer. JCO Clin Cancer Inform. 2024 Dec; 8:e2400133.
-
Determining Line of Therapy from Real-World Data in Non-Small Cell Lung Cancer. Pharmacoepidemiol Drug Saf. 2024 12; 33(12):e70049.
-
Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non-Small Cell Lung Cancer. Cancer Discov. 2024 Nov 01; 14(11):2183-2208.
-
Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer. J Immunother Cancer. 2024 Oct 23; 12(10).